Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acetylsalicylic acid + dimethyl fumarate is a proprietary combination drug that pairs aspirin with dimethyl fumarate to reduce the incidence and severity of fumarate flush, a common side effect of dimethyl fumarate therapy in multiple sclerosis patients. Dimethyl fumarate is used to treat relapsing forms of multiple sclerosis, while the addition of aspirin helps mitigate the flushing side effect without affecting the pharmacokinetic profile of dimethyl fumarate or causing additional gastrointestinal events. In clinical studies, this combination has shown a 63% reduction in flush compared to fumarate alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetylsalicylic acid + dimethyl fumarate.